Login / Signup

MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.

Sebastian BrandnerAlexandra McAleenanClaire KellyFrancesca SpigaHung-Yuan ChengSarah DawsonLena SchmidtClaire L FaulknerChristopher WraggSarah JefferiesJulian P T HigginsKathreena M Kurian
Published in: Neuro-oncology (2021)
We cannot draw strong conclusions about use of frozen tissue vs formalin-fixed paraffin-embedded in MSP and PSQ. Also, our meta-analysis does not provide strong evidence about the best CpG sites or threshold. MSP has been studied mainly for CpG sites 76-80 and 84-87 and PSQ at CpG sites ranging from 72 to 95. A cutoff threshold of 9% for CpG sites 74-78 performed better than higher thresholds of 28% or 29% in 2 of the 3 good-quality studies. About 190 studies were identified presenting HRs from survival analysis in patients in which MGMT methylation was measured by 1 technique only.
Keyphrases